Edward Michael Collins, APN | |
703 Main St, Paterson, NJ 07503-2621 | |
(973) 754-2240 | |
Not Available |
Full Name | Edward Michael Collins |
---|---|
Gender | Male |
Speciality | Nurse Practitioner - Acute Care |
Location | 703 Main St, Paterson, New Jersey |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1144373705 | NPI | - | NPPES |
0144843 | Medicaid | NJ |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
163WE0003X | Registered Nurse - Emergency | 26NO111105 (New Jersey) | Secondary |
363LA2100X | Nurse Practitioner - Acute Care | 26NJ00128900 (New Jersey) | Primary |
Entity Name | Hackensack Meridian Health Medical Group - Specialty Care Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1215989249 PECOS PAC ID: 9133032519 Enrollment ID: O20031111000524 |
News Archive
Premiums in California's health insurance exchange will rise by an average of 8.7 percent next year, marking a return to more modest increases despite ongoing threats to the Affordable Care Act.
Merck Serono, a division of Merck KGaA, Darmstadt, Germany has announced that new data presented today at the 35th Congress of the European Society for Medical Oncology (ESMO) have shown that patients with KRAS wild-type metastatic colorectal cancer (mCRC) who experienced early tumor shrinkage (within 8 weeks) during 1st line Erbitux (cetuximab) based treatment lived a median of 28.3 months.
GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved raxibacumab for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.
Memory Pharmaceuticals Corp. has announced the issuance of U.S. Patent No. 7,429,664, which provides composition of matter patent protection for a series of nicotinic alpha-7 receptor agonists.
› Verified 1 days ago
Entity Name | St Josephs Healthcare Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1497791297 PECOS PAC ID: 9739171984 Enrollment ID: O20040330001612 |
News Archive
Premiums in California's health insurance exchange will rise by an average of 8.7 percent next year, marking a return to more modest increases despite ongoing threats to the Affordable Care Act.
Merck Serono, a division of Merck KGaA, Darmstadt, Germany has announced that new data presented today at the 35th Congress of the European Society for Medical Oncology (ESMO) have shown that patients with KRAS wild-type metastatic colorectal cancer (mCRC) who experienced early tumor shrinkage (within 8 weeks) during 1st line Erbitux (cetuximab) based treatment lived a median of 28.3 months.
GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved raxibacumab for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.
Memory Pharmaceuticals Corp. has announced the issuance of U.S. Patent No. 7,429,664, which provides composition of matter patent protection for a series of nicotinic alpha-7 receptor agonists.
› Verified 1 days ago
Entity Name | Faster Urgent Care, Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1326291253 PECOS PAC ID: 8123177896 Enrollment ID: O20090529000100 |
News Archive
Premiums in California's health insurance exchange will rise by an average of 8.7 percent next year, marking a return to more modest increases despite ongoing threats to the Affordable Care Act.
Merck Serono, a division of Merck KGaA, Darmstadt, Germany has announced that new data presented today at the 35th Congress of the European Society for Medical Oncology (ESMO) have shown that patients with KRAS wild-type metastatic colorectal cancer (mCRC) who experienced early tumor shrinkage (within 8 weeks) during 1st line Erbitux (cetuximab) based treatment lived a median of 28.3 months.
GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved raxibacumab for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.
Memory Pharmaceuticals Corp. has announced the issuance of U.S. Patent No. 7,429,664, which provides composition of matter patent protection for a series of nicotinic alpha-7 receptor agonists.
› Verified 1 days ago
Mailing Address | Practice Location Address |
---|---|
Edward Michael Collins, APN 24 Shadyside Rd, Hewitt, NJ 07421-2311 Ph: (201) 406-8786 | Edward Michael Collins, APN 703 Main St, Paterson, NJ 07503-2621 Ph: (973) 754-2240 |
News Archive
Premiums in California's health insurance exchange will rise by an average of 8.7 percent next year, marking a return to more modest increases despite ongoing threats to the Affordable Care Act.
Merck Serono, a division of Merck KGaA, Darmstadt, Germany has announced that new data presented today at the 35th Congress of the European Society for Medical Oncology (ESMO) have shown that patients with KRAS wild-type metastatic colorectal cancer (mCRC) who experienced early tumor shrinkage (within 8 weeks) during 1st line Erbitux (cetuximab) based treatment lived a median of 28.3 months.
GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved raxibacumab for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.
Memory Pharmaceuticals Corp. has announced the issuance of U.S. Patent No. 7,429,664, which provides composition of matter patent protection for a series of nicotinic alpha-7 receptor agonists.
› Verified 1 days ago
Susan Mugalu, ANP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 703 Main St, Paterson, NJ 07503 Phone: 973-754-0000 | |
Diane E Mcclure, CPNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 703 Main St, Paterson, NJ 07503 Phone: 973-754-2555 Fax: 973-754-2567 | |
Cynthia Dayrit -demetillo, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1040 Main St, Paterson, NJ 07503 Phone: 973-782-6615 Fax: 973-782-6618 | |
Mrs. Kathleen Ann Connolly, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 393 Main St, Paterson, NJ 07501 Phone: 973-523-6220 Fax: 973-825-7201 | |
Mr. Michael Pasquale, MSN, RN, APN-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 703 Main St, Paterson, NJ 07503 Phone: 973-754-3857 | |
Nidia Ortega, APN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 416 Park Ave, Paterson, NJ 07504 Phone: 973-684-8138 Fax: 973-684-0032 | |
Kassidy Katona, APN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 680 Broadway Ste 104, Paterson, NJ 07514 Phone: 973-239-9400 |